Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Emapalumab Preventie van CAR-T-celgeassocieerde toxiciteiten

1 oktober 2026 bijgewerkt door: Marcela V. Maus, M.D.,Ph.D.

Een fase 2-studie van Emapalumab voor de preventie van CAR-T-celgeassocieerde toxiciteiten

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).

The research study involves the following study interventions:

  • Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
  • Axicabtagene Ciloleucel or Lisocabtagene Maraleucel
  • Emapalumab

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

This is a phase 2 multi-center, open label study that is evaluating the safety and efficacy of emapalumab in preventing toxicities associated with FDA Approved, CD19-directed CAR-T in subjects with second- or third-line large B-cell non-Hodgkin's lymphoma.

A phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

The U.S. Food and Drug Administration (FDA) has not approved emapalumab for the participants specific disease, but it has been approved for other uses.

The U.S. FDA has approved axicabtagene ciloleucel and lisocabtagene maraleucel for the participants specific disease.

This research study procedures include screening for eligibility, study treatment including collection of T cells (leukapheresis), lymphodepleting chemotherapy, treatment with emapalumab and axicabtagene ciloleucel or lisocabtagene maraleucel, and follow-up evaluations.

Once study treatment is completed, the participants will be followed for up to 24 months.

It is expected that about 28 people will take part in this research study.

Studietype

Ingrijpend

Inschrijving (Geschat)

28

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Werving
        • Massachusetts General Hospital
        • Hoofdonderzoeker:
          • Matthew Frigault, MD
        • Contact:
      • Boston, Massachusetts, Verenigde Staten, 02215

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Or adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

  • At least 1 measurable lesion per Lugano at time of screening.

  • Age 18 or older

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Adequate renal, hepatic, pulmonary and cardiac function defined as:

    • ANC ≥1000/uL
    • Platelet count ≥50,000/uL
    • Absolute lymphocyte count ≥100/uL
    • Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL/min
    • Serum ALT/AST ≤2.5 per institutional ULN
    • Total bilirubin ≤1.5 mg/dl, except in subjects with Gilbert's syndrome.
    • Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings
    • Baseline oxygen saturation >92% on room air.
  • Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).

  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years.

  • Autologous stem cell transplant within 6 weeks of planned CAR-T infusion.

  • History of allogeneic stem cell transplantation.

  • Presence of uncontrolled fungal, bacterial, viral, or other infection at time of screening.

  • Known history of acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines.

    • Patients should also be negative for latent Tb, CMV (NAT), EBV (NAT) and adenovirus (NAT) by PCR testing.
  • No evidence of active CNS disease regardless of prior CNS history.

  • History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage within 6 months of enrollment.

  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.

  • History of symptomatic pulmonary embolism within 3 months of enrollment; ongoing anticoagulation is allowed if beyond 3 months.

  • Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.

  • History of allergic reactions or severe immediate hypersensitivity reaction to any of the agents used in this study or compounds of similar chemical or biologic composition.

  • Females who are pregnant or breastfeeding or female or male participants who are not willing to practice birth control from the time of consent through 6 months after the completion of CAR-T

  • In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.

  • History of autoimmune disease requiring ongoing systemic immunosuppression. Steroids are allowed up to 5mg predinosine-equivalent for adrenal insufficiency.

  • Receipt of a BCG vaccine within 12 weeks prior to Screening.

  • Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screeing.

  • Participants who are receiving any other investigational agents for this condition.

  • Patients anticipated to require canakinumab, JAK inhibitors, TNF inhibitors, and tocilizumab for non-CAR-T management of baseline autoimmune/inflammatory disease at the time of emapalumab initiation.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Cohort 1a

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Patients will receive emapalumab 3mg/kg on day -1.

FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes.

An interferon gamma (IFNγ) blocking antibody

Andere namen:
  • Gamifant
  • Humaan anti-interferon gamma (IFNγ) monoklonaal antilichaam

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

Experimenteel: Cohort 1b

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes.

Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2.

Patients will receive emapalumab 3mg/kg on day +1.

An interferon gamma (IFNγ) blocking antibody

Andere namen:
  • Gamifant
  • Humaan anti-interferon gamma (IFNγ) monoklonaal antilichaam

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

Corticosteroid

Experimenteel: Cohort 2a

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Patients will receive emapalumab 3mg/kg on day -1.

Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes.

An interferon gamma (IFNγ) blocking antibody

Andere namen:
  • Gamifant
  • Humaan anti-interferon gamma (IFNγ) monoklonaal antilichaam

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

Experimenteel: Cohort 2b

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes.

Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2.

Patients will receive emapalumab 3mg/kg on day +1.

An interferon gamma (IFNγ) blocking antibody

Andere namen:
  • Gamifant
  • Humaan anti-interferon gamma (IFNγ) monoklonaal antilichaam

Alkylating agent

Purine antagonist antimetabolite

Corticosteroid

Autologous treatment

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of grade 2+ CRS per ASTCT
Tijdsspanne: Day -1 to 24 months post treatment

Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). All participants will be monitored and assessed for grade 2+ cytokine release syndrome (CRS) for 24 months after post treatment.

Day -1 to 24 months post treatment

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Rate and severity of ICANS as per ASTCT
Tijdsspanne: 30 days

Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). The rate and severity of immune cell associated neurotoxicity syndrome (ICANS) within the first 30 days of infusion.

30 days
Objective response rate (ORR)
Tijdsspanne: Day -1 to 24 months post treatment

The incidence of either a complete response or a partial response by Lugano. All subjects that do not meet the criteria for an objective response by the analysis data cutoff date will be considered non-responders.

Day -1 to 24 months post treatment

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Duration of response (DOR)
Tijdsspanne: From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment

Among subject who experience an objective response the date of their first objective response to disease progression per Lugano or death regardless of cause. Subjects not meeting the criteria for progression or death by the analysis data cutoff date will be censored at their last evaluable disease assessment date and their response will be noted as ongoing.

From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
Progression-free Survival (PFS)
Tijdsspanne: From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment

The time from the CAR-T infusion date to the date of disease progression per Lugano or death from any cause. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.

From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
Overall survival (OS)
Tijdsspanne: From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment

The time from CAR-T infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date.

From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Matthew Frigault, MD, Massachusetts General Hospital

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

18 september 2024

Primaire voltooiing (Geschat)

1 augustus 2027

Studie voltooiing (Geschat)

1 augustus 2028

Studieregistratiedata

Eerst ingediend

5 augustus 2024

Eerst ingediend dat voldeed aan de QC-criteria

8 augustus 2024

Eerst geplaatst (Werkelijk)

12 augustus 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

1 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD-tijdsbestek voor delen

Data can be shared no earlier than 1 year following the date of publication

IPD-toegangscriteria voor delen

Contact the Partners Innovations team at http://www.partners.org/innovation

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .